Frequently Asked Questions
The market is segmented based on , By Drugs (Metronidazole, Vancomycin, Fidaxomicin, Metronidazole, Probiotics, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2030.
.
The Global Clostridium Difficile Infection Drugs Market size was valued at USD 8.58 USD Billion in 2022.
The Global Clostridium Difficile Infection Drugs Market is projected to grow at a CAGR of 7% during the forecast period of 2023 to 2030.
The major players operating in the market include Novartis AG, Baxter, ANI Pharmaceuticals , Mylan N.V., Akorn, Sun Pharmaceutical Industries , Merck & Co. , B. Braun Medical , Teva Pharmaceutical Industries , Hikma Pharmaceutical PLC, Perrigo Pharmaceutical, Apotex , AbbVie , Fresenius Kabi USA, Pfizer , Strides Pharma Science Limited, Sanofi, AstraZeneca, Eli Lilly and Company, Actelion Pharmaceuticals , Astellas Pharma.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.
